세계의 오가노이드 및 스페로이드 시장 : 규모, 점유율 및 동향 분석(유형별, 용도별, 최종 용도별, 지역별), 부문별 예측(2025-2030년)

Organoids And Spheroids Market Size, Share & Trends Analysis Report By Type, By Application (Developmental Biology, Personalized Medicine, Regenerative Medicine), By End Use, By Region And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,269,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,659,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,438,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 오가노이드 및 스페로이드 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 오가노이드 및 스페로이드 시장 규모는 2025년부터 2030년까지 23.23%의 연평균 복합 성장률(CAGR)을 기록하며, 2030년까지 62억 7,000만 달러에 달할 것으로 예측됩니다.

신약개발에서의 유기농 배양 채용 증가와 세계 세포요법과 조직공학 수요 증가가 시장을 견인할 것으로 예측되고 있습니다.

3D 스페로이드는 복잡한 조직과 장기를 생성하기 위한 빌딩 블록으로 사용할 수 있기 때문에 조직 공학 및 재생 의료 연구의 중요한 측면으로 여겨지고 있습니다.

인간 특유 질환의 메커니즘 평가에 오가노이드 배양을 채용하는 움직임이 활발해지고 있으며, 시장의 성장이 기대됩니다. 인간 장기와 유사한 3D 세포 배양의 생성은 세포 요법으로 오가노이드의 사용과 전체 장기 이식의 대안으로 가능성에 큰 가능성을 가져왔습니다.

오가노이드 및 스페로이드 시장 : 분석 개요

• 유형별로는 오가노이드의 부문이 2024년에 59.65%의 최대 매출 점유율로 시장을 리드했습니다.
• 용도별로는 발생 생물학 분야가 2024년에 30.17%의 최대 수익 점유율로 시장을 선도했습니다.
• 최종 용도별로는 바이오테크놀로지 및 제약 산업 분야가 2024년에 46.32%의 최대 수익 점유율로 시장을 리드했습니다.
• 북미가 오가노이드 및 스페로이드 시장을 독점해, 2024년에는 34.72%의 최대 수익 점유율을 차지했습니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 오가노이드 및 스페로이드 시장 : 변동 요인, 경향, 범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 오가노이드 및 스페로이드 시장 : 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 유형별 비즈니스 분석

• 부문 대시보드
• 세계의 오가노이드 및 스페로이드 시장 : 유형별 변동 분석
• 세계의 오가노이드 및 스페로이드 시장 : 시장 규모와 동향 분석, 유형별(2018-2030년)
• 오가노이드
  • 오가노이드 : 시장의 추계 및 예측(2018-2030년)
  • 오가노이드 : 유형별
  • 오가노이드 : 수법별
  • 오가노이드 : 원료별
• 스페로이드
  • 스페로이드 : 시장의 추계 및 예측(2018-2030년)
  • 스페로이드 : 유형별
  • 스페로이드 : 수법별
  • 스페로이드 : 원료별

제5장 최종 용도별 비즈니스 분석

• 부문 대시보드
• 세계의 오가노이드 및 스페로이드 시장 : 최종 용도별 변동 분석
• 세계의 오가노이드 및 스페로이드 시장 : 시장 규모와 동향 분석, 최종 용도별(2018-2030년)
• 바이오테크놀러지 및 제약산업
  • 바이오테크놀러지 및 제약산업: 시장의 추계 및 예측(2018-2030년)
• 학술연구기관
  • 학술연구기관 : 시장의 추계 및 예측(2018-2030년)
• 병원 및 진단센터
  • 병원 및 진단센터 : 시장의 추계 및 예측(2018-2030년)

제6장 용도별 비즈니스 분석

• 부문 대시보드
• 세계의 오가노이드 및 스페로이드 시장 : 용도별 변동 분석
• 세계의 오가노이드 및 스페로이드 시장 : 시장 규모와 동향 분석, 용도별(2018-2030년)
• 발생 생물학
  • 발생 생물학: 시장의 추계 및 예측(2018-2030년)
• 맞춤형 의료
  • 맞춤형 의료 : 시장의 추계 및 예측(2018-2030년)
• 재생 의료
  • 재생의료 : 시장의 추계 및 예측(2018-2030년)
• 질병 병리학 연구
  • 질병 병리학 연구 : 시장의 추계 및 예측(2018-2030년)
• 약물 독성 및 유효성 시험
  • 약물 독성 및 유효성 시험 : 시장의 추계 및 예측(2018-2030년)

제7장 지역별 비즈니스 분석(국가별, 유형별, 용도별, 최종 용도별)

• 부문 대시보드
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 북미 : 시장의 추계 및 예측(2018-2030년)
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽 : 시장의 추계 및 예측(2018-2030년)
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양: 시장의 추계 및 예측(2018-2030년)
  • 중국
  • 일본
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 라틴아메리카: 시장의 추계 및 예측(2018-2030년)
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카: 시장의 추계 및 예측(2018-2030년)
  • 사우디아라비아
  • 남아프리카
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 기업 분류
• 전략 매핑
• 기업 포지션 분석(2024년)
• 기업 프로파일/상장 기업
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Lonza
  • 3D Biomatrix
  • 3D Biotek LLC
  • AMS Biotechnology(Europe)Limited
  • Cellesce Ltd
  • Corning Incorporated
  • Greiner Bio-One
  • Hubrecht Organoid Technology(HUB)
  • InSphero
  • Prellis Biologics
  • STEMCELL Technologies Inc.

JHS

영문 목차

영문목차

Organoids And Spheroids Market Growth & Trends:

The global organoids and spheroids market size is expected to reach USD 6.27 billion by 2030, registering a CAGR of 23.23% from 2025 to 2030, according to a new report by Grand View Research, Inc., A rise in the adoption of organoid cultures in drug discovery, and rising demand for cell therapy and tissue engineering across the globe is expected to drive the market.

3D spheroids are considered as an important aspect of tissue engineering and regenerative medicine research as they can be used as building blocks for the generation of complex tissues and organs. In addition, the potential of 3D cell cultures to be used as models for drug screening and analysis of human disorders are expected to provide ample growth opportunities to the market in the near future.

A rise in the adoption of organoid cultures for the assessment of the mechanism of human-specific disorders is expected to enhance the market growth. For instance, human organoids have helped in the analysis of a wide range of tissues including the small intestine, prostate, brain, and liver. The promise of the generation of 3D cell cultures that resemble human organs has brought an enormous potential for the use of organoids as cell therapies, and as prospective substitutes for whole-organ transplantation.

Organoids And Spheroids Market Report Highlights:

• Based on type, the organoids segment led the market with the largest revenue share of 59.65% in 2024. The organoid market is primarily driven by the increasing demand for physiologically relevant 3D cell culture models in drug discovery, disease modeling, and personalized medicine.
• Based on application, the developmental biology segment led the market with the largest revenue share of 30.17% in 2024, owing to the rising usage of organoid and spheroid culture systems for developmental biology.
• Based on end use, the biotechnology and pharmaceutical industries segment led the market with the largest revenue share of 46.32% in 2024.
• North America dominated the organoids and spheroids market with the largest revenue share of 34.72% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Application
  • 1.1.3. End Use
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Organoids & Spheroids Market Variables and Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High adoption of organoids & spheroids in drug discovery
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Rising demand for tissue engineering & organ transplantation
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Challenges associated with 3D cell culturing
    • 3.2.2.2. Ethical issues associated with organoid & spheroid cultures
• 3.3. Organoids & Spheroids Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Organoids & Spheroids Market: Type Movement Analysis
• 4.3. Global Organoids & Spheroids Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Organoids
  • 4.4.1. Organoids market estimates and forecast, 2018 - 2030
  • 4.4.2. Organoids by Type
    • 4.4.2.1. Neural Organoids
      • 4.4.2.1.1. Neural organoids market estimates and forecast, 2018 - 2030
    • 4.4.2.2. Hepatic Organoids
      • 4.4.2.2.1. Hepatic organoids market estimates and forecast, 2018 - 2030
    • 4.4.2.3. Intestinal organoids
      • 4.4.2.3.1. Intestinal organoids market estimates and forecast, 2018 - 2030
    • 4.4.2.4. Other organoids
      • 4.4.2.4.1. Other organoids market estimates and forecast, 2018 - 2030
  • 4.4.3. Organoids by Method
    • 4.4.3.1. General Submerged Method for Organoid Culture
      • 4.4.3.1.1. General Submerged Method for Organoid Culture market estimates and forecast, 2018 - 2030
    • 4.4.3.2. Crypt Organoid Culture Techniques
      • 4.4.3.2.1. Crypt Organoid Culture Techniques market estimates and forecast, 2018 - 2030
    • 4.4.3.3. Air Liquid Interface (ALI) Method for Organoid Culture
      • 4.4.3.3.1. ALI Method for Organoid Culture market estimates and forecast, 2018 - 2030
    • 4.4.3.4. Clonal Organoids from Lgr5+ Cells
      • 4.4.3.4.1. Clonal Organoids from Lgr5+ Cells market estimates and forecast, 2018 - 2030
    • 4.4.3.5. Brain and Retina Organoid Formation Protocol
      • 4.4.3.5.1. Brain and Retina Organoid Formation Protocol market estimates and forecast, 2018 - 2030
    • 4.4.3.6. Others
      • 4.4.3.6.1. Others market estimates and forecast, 2018 - 2030
  • 4.4.4. Organoids by Source
    • 4.4.4.1. Primary Tissues
      • 4.4.4.1.1. Primary tissues market estimates and forecast, 2018 - 2030
    • 4.4.4.2. Stem Cells
      • 4.4.4.2.1. Stem cells market estimates and forecast, 2018 - 2030
• 4.5. Spheroids
  • 4.5.1. Spheroids market estimates and forecast, 2018 - 2030
  • 4.5.2. Spheroids by Type
    • 4.5.2.1. Multicellular tumor spheroids (MCTS)
      • 4.5.2.1.1. MCTS market estimates and forecast, 2018 - 2030
    • 4.5.2.2. Neurospheres
      • 4.5.2.2.1. Neurospheres market estimates and forecast, 2018 - 2030
    • 4.5.2.3. Mammospheres
      • 4.5.2.3.1. Mammospheres market estimates and forecast, 2018 - 2030
    • 4.5.2.4. Hepatospheres
      • 4.5.2.4.1. Hepatospheres market estimates and forecast, 2018 - 2030
    • 4.5.2.5. Embryoid bodies
      • 4.5.2.5.1. Embryoid bodies market estimates and forecast, 2018 - 2030
  • 4.5.3. Spheroids by Method
    • 4.5.3.1. Micropatterned Plates
      • 4.5.3.1.1. Micropatterned Plates market estimates and forecast, 2018 - 2030
    • 4.5.3.2. Low Cell Attachment Plates
      • 4.5.3.2.1. Low Cell Attachment Plates market estimates and forecast, 2018 - 2030
    • 4.5.3.3. Hanging Drop Method
      • 4.5.3.3.1. Hanging Drop Method for spheroid Culture market estimates and forecast, 2018 - 2030
    • 4.5.3.4. Others
      • 4.5.3.4.1. Other methods for spheroid culture market estimates and forecast, 2018 - 2030
  • 4.5.4. Spheroids by Source
    • 4.5.4.1. Cell Line
      • 4.5.4.1.1. Cell line market estimates and forecast, 2018 - 2030
    • 4.5.4.2. Primary Cell
      • 4.5.4.2.1. Primary cell market estimates and forecast, 2018 - 2030
    • 4.5.4.3. iPSCs Derived Cells
      • 4.5.4.3.1. iPSCs Derived Cells market estimates and forecast, 2018 - 2030

Chapter 5. End Use Business Analysis

• 5.1. Segment Dashboard
• 5.2. Global Organoids & Spheroids Market: End Use Movement Analysis
• 5.3. Global Organoids & Spheroids Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Biotechnology and Pharmaceutical Industries
  • 5.4.1. Biotechnology and Pharmaceutical Industries market estimates and forecast 2018 to 2030 (USD million)
• 5.5. Academic & Research Institutes
  • 5.5.1. Academic & Research Institutes market estimates and forecast 2018 to 2030 (USD Million)
• 5.6. Hospitals and Diagnostic Centers
  • 5.6.1. Hospitals and Diagnostic Centers market estimates and forecast 2018 to 2030 (USD million)

Chapter 6. Application Business Analysis

• 6.1. Segment Dashboard
• 6.2. Global Organoids & Spheroids Market: Application Movement Analysis
• 6.3. Global Organoids & Spheroids Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Developmental Biology
  • 6.4.1. Developmental Biology market estimates and forecast 2018 to 2030 (USD million)
• 6.5. Personalized Medicine
  • 6.5.1. Personalized Medicine market estimates and forecast 2018 to 2030 (USD Million)
• 6.6. Regenerative Medicine
  • 6.6.1. Regenerative Medicine market estimates and forecast 2018 to 2030 (USD million)
• 6.7. Disease Pathology Studies
  • 6.7.1. Disease Pathology Studies market estimates and forecast 2018 to 2030 (USD Million)
• 6.8. Drug Toxicity & Efficacy Testing
  • 6.8.1. Drug Toxicity & Efficacy Testing market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Regional Business Analysis, By Country, Type, Application, & End Use

• 7.1. Segment Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. North America Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Target Disease Prevalence
    • 7.3.2.3. Competitive Scenario
    • 7.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Canada market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target Disease Prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. Mexico market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 7.4. Europe
  • 7.4.1. Europe Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. UK market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Germany market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. France market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Italy market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Spain market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. Denmark market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Target Disease Prevalence
    • 7.4.8.3. Competitive Scenario
    • 7.4.8.4. Sweden market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Target Disease Prevalence
    • 7.4.9.3. Competitive Scenario
    • 7.4.9.4. Norway market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.2. China
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. China market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.3. Japan
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Japan market estimates and forecast, 2018 - 2030 (Volume, Thousand)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. India market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Competitive Scenario
    • 7.5.5.4. Australia market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Competitive Scenario
    • 7.5.6.4. Thailand market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Competitive Scenario
    • 7.5.7.4. South Korea market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 7.6. Latin America
  • 7.6.1. Latin America Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. Brazil market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Argentina market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 7.7. MEA
  • 7.7.1. MEA Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Competitive Scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.7.3. South Africa
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Competitive Scenario
    • 7.7.3.4. South Africa market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Target Disease Prevalence
    • 7.7.4.3. Competitive Scenario
    • 7.7.4.4. UAE market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Target Disease Prevalence
    • 7.7.5.3. Competitive Scenario
    • 7.7.5.4. Kuwait market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Merck KGaA
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Lonza
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. 3D Biomatrix
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. 3D Biotek LLC
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. AMS Biotechnology (Europe) Limited
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Cellesce Ltd
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Corning Incorporated
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Greiner Bio-One
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Hubrecht Organoid Technology (HUB)
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. InSphero
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. Prellis Biologics
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Product benchmarking
    • 8.4.12.4. Strategic initiatives
  • 8.4.13. STEMCELL Technologies Inc.
    • 8.4.13.1. Company overview
    • 8.4.13.2. Financial performance
    • 8.4.13.3. Product benchmarking
    • 8.4.13.4. Strategic initiatives

관련자료